Humacyte COO Dr. Heather Prichard joins the Business of Biotech for a discussion on the company's pipeline of candidates for the repair, replacement, and reconstruction of human vascular vessels. The company recently scaled the production of its implantable bioengineered human tissues from 10 to 200 per day to meet Phase 3 vascular trauma and arteriovenous access trials. On today's episode, Dr. Prichard shares the company's scale-up story and the science and engineering behind a unique approach to regenerative medicine using human tissue.
#businessofbiotech #biopharma #biotech #cytiva
[ Ссылка ]
Audio version available here: [ Ссылка ]
Subscribe to the podcast:
Apple - [ Ссылка ]
Spotify - [ Ссылка ]
Google - [ Ссылка ]
